Serum Albumin Predicts Survival in Indian Adult Diffuse Large B cell Lymphoma Patients in the Rituximab Era

Abstract

Objective: The present study was done to evaluate the prognostic impact of the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) and serum albumin levels in the treatment outcome of Indian diffuse large B-cell lymphoma (DLBCL) patients in the rituximab era. Patients and Methods: We retrospectively analyzed the data (2013–2016) of 135 newly diagnosed DLBCL cases ≥18 years of age. All patients received Rituximab-Cyclophosphamide, Adriamycin, Vincristine, Prednisone (R-CHOP) chemotherapy. The analysis was carried out to assess the overall survival (OS) and progression-free survival (PFS) and the prognostic factors predicting the outcome. Results: Of the 135 patients in the study, 89 (65.9%) had B-symptoms, 20 (14.8%) had bulky disease, 79 (58.5%) had advanced disease (Stage III and IV), and 29 (21.5%) had primary extranodal involvement. Serum albumin ≤3.5 g% was present in 71 (52.6%) patients. About 74 (54.8%) cases were risk stratified to NCCN-IPI high-intermediate-risk group, while 18 (13.3%) patients were categorized into high-risk group. The median PFS and OS of our study cohort were 19 months (95% confidence interval [CI] = 2.59–35.4) and 38 months (95% CI = 9.02–55.68), respectively. Serum albumin ≤3.5 g/dl was significantly associated with poor OS (hazard ratio [HR] = 3.99, 95% CI = 2.25–7.07, P < 0.001) and PFS (HR = 3.71, 95% CI = 2.20–6.26, P < 0.002). Similarly, low NCCN-IPI (<4) was significantly associated with improved OS (HR = 0.21, 95% CI = 0.09–0.47, P < 0.005) and PFS (HR = 0.19, 95% CI = 0.09–0.41, P < 0.001), respectively. These two factors (serum albumin and NCCN-IPI) retained their prognostic significance with respect to OS and PFS in the multivariate analysis. Conclusion: The NCCN-IPI prognostic model and serum albumin levels have independent prognostic significance in Indian DLBCL patients. Serum albumin is a readily available, easy to standardize, and cheap investigation requiring no specialized expertise and holds promise for being incorporated in future DLBCL prognostic risk models.

Keywords

Albumin - diffuse large B-cell lymphoma - National Comprehensive Cancer Network-International Prognostic Index - prognosis

• References

• 1 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-76
• 2 International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94
• 3 Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61
• 4 Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P. et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: A never-ending story. Ann Oncol 2010; 21: 1486-91
• 5 Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123: 837-42
• 6 Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y. et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the international DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-13
• 7 Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 402-9
• 8 Perry AM, Mitrovic Z, Chan WC. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19: 214-26
• 9 Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC. et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121: 2253-63
• 10 Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H. et al. Analysis of prognostic factors in peripheral T-cell lymphoma: Prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009; 50: 1999-2004
• 11 Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol 2015; 33: 2863-9
• 12 Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y. et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 2010; 51: 813-21
• 13 Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ, Lin TY. et al. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: Clinical characteristics and prognostic factors. Int J Hematol 2011; 94: 178-84
• 14 Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14
• 15 Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M. et al. Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood 2006; 107: 4643-9
• 16 Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE. et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 2012; 87: 1006-9
• 17 Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J. et al. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2011; 17: 384-93
• 18 Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J 2010; 9: 69
• 19 Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50: 693-703
• 20 Franch-Arcas G. The meaning of hypoalbuminaemia in clinical practice. Clin Nutr 2001; 20: 265-9
• 21 Barchel D, Almoznino-Sarafian D, Shteinshnaider M, Tzur I, Cohen N, Gorelik O. Clinical characteristics and prognostic significance of serum albumin changes in an internal medicine ward. Eur J Intern Med 2013; 24: 772-8
• 22 Swerdlow SH, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency of Research on Cancer Scientific Publications; 2016
• 23 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014; 32: 3059-68
• 24 Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N. et al. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 2017; 96: 1-8
• 25 Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W. et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin. Br J Haematol 2015; 168: 239-45
• 26 Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH. et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014; 93: 1305-12
• 27 Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: An important simple prognostic factor. Hematol Oncol 2016; 34: 184-92
• 28 Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK. B cell non-Hodgkin's lymphoma: Experience from a tertiary care cancer center. Ann Hematol 2012; 91: 1603-11
• 29 Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R. Diffuse large B-cell lymphoma: Experience from a tertiary care center in North India. Med Oncol 2010; 27: 310-8
• 30 Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP. et al. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma 2008; 49: 462-9
• 31 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54
• 32 McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001; 39: 210-3
• 33 Aviles A, Yañez J, López T, García EL, Guzmán R, Díaz-Maqueo JC. Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 1995; 26: 31-4
• 34 Hong JY, Ryu KJ, Lee JY, Park C, Ko YH, Kim WS. et al. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol 2016; 12: 1-7
• 35 Lv X, Feng L, Ge X, Lu K, Wang X. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 2016; 35: 106
• 36 Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B. et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006; 17: 60-6
• 37 D'Angio RG. Is there a role for albumin administration in nutrition support?. Ann Pharmacother 1994; 28: 478-82
• 38 Yamasaki K, Chuang VT, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 2013; 1830: 5435-43